# Pacira Pharmaceuticals

> Pacira Pharmaceuticals is a VC fund backing Biotechnology and Medical. See 11 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Diego, United States
- Total investments: 11
- Last investment: Feb 2023
- Lead investor: 82%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/pacira-pharmaceuticals-inc.
- Website: http://www.pacira.com
- Facebook: http://www.facebook.com/pages/Pacira-Pharmaceuticals/180221595381303

Pacira Pharmaceuticals is a VC fund in San Diego focused on Biotechnology and Medical. Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.

## Contacts

5 contacts available for Pacira Pharmaceuticals. Shizune tracks 6 team members at Pacira Pharmaceuticals. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pacira-pharmaceuticals?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Medical | 4 | 36% |
| Health Care | 3 | 27% |
| Pharmaceutical | 3 | 27% |
| Genetics | 1 | 9% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Convertible Note | 3 | 27% |
| Series A | 2 | 18% |
| Seed | 1 | 9% |
| Series B | 1 | 9% |
| Funding Round | 1 | 9% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 45% |
| Germany | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Charles A. Reinhart III | Chief Financial Officer | 0 | https://shizune.co/investors/profile/charles-a-reinhart-iii |
| Dennis McLoughlin | Area Sales Director | 1 | https://shizune.co/investors/profile/dennis-mcloughlin |
| Paul R. Ellwood | Vice President, Human Resources | 0 | https://shizune.co/investors/profile/paul-r-ellwood |
| Donald C. Manning | Chief Medical Officer | 0 | https://shizune.co/investors/profile/donald-c-manning |
| John Bartolick | Vice President IT | 0 | https://shizune.co/investors/profile/john-bartolick |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M | Convertible Note | Feb 08, 2023 | https://www.spinebiopharma.com/ |
| CarthroniX | CarthroniX is a pharmaceutical company that offers small molecule based therapy, wound healing, skin regeneration, and novel solutions. | $2.3M | Convertible Note | Apr 11, 2022 | https://www.carthronix.com |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M | Series B | Mar 23, 2022 | https://www.spinebiopharma.com/ |
| Genascence | Clinical-stage biotechnology company developing life-changing gene therapy products for musculoskeletal diseases | $10.5M | Series A | Jan 07, 2022 | https://genascence.com |
| CODA Biotherapeutics | CODA Biotherapeutics develops a chemogenetic platform designed to modulate neuronal activity. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwiseinactive. The interaction of the small molecule and engineered receptor allows for exquisite, dose-dependent control of the neurons to generate the therapeutic effect. | $28M | Venture - Series Unknown | Dec 02, 2021 | https://www.codabiotherapeutics.com/ |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $3M | Convertible Note | Apr 20, 2021 | https://www.spinebiopharma.com/ |
| GeneQuine Biotherapeutics | GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $6.6M | Series A | Feb 15, 2021 | http://www.genequine.com/de/ |
| GeneQuine Biotherapeutics | GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $3.1M | Debt Financing | Feb 15, 2021 | http://www.genequine.com/de/ |
| GeneQuine Biotherapeutics | GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse. | $3.3M | Convertible Note | Feb 15, 2021 | http://www.genequine.com/de/ |
| AVALON.AI | AVALON.AI is a Healthcare company that features an AI solution for real-time analysis using various data sources to generate a heat map of the areas that are affected by the pandemics like Coronavirus from a global to a hyper-local level. Its enterprise solution supports all business, government, educational, and healthcare silos. | $1.5M | Seed | Aug 28, 2020 | https://avalonai.co |

10 of 11 investments shown.

## Co-investors
- [Cercano Management](https://shizune.co/investors/profile/cercano-management) — VC Fund, 2 deals together
- [Viscogliosi Brothers](https://shizune.co/investors/profile/viscogliosi-brothers) — VC Fund, 2 deals together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together
- [Meusinvest (Noshaq)](https://shizune.co/investors/profile/meusinvest) — VC Fund, 1 deal together
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 1 deal together
- [Polymerase Capital](https://shizune.co/investors/profile/polymerase-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund

### Similar country
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund
- [HV Capital](https://shizune.co/investors/profile/holtzbrinck-ventures) — VC Fund
- [IBB Ventures](https://shizune.co/investors/profile/ibb) — VC Fund

## Featured in investor lists
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Biotechnology VC Funds in Germany](https://shizune.co/investors/biotechnology-vc-funds-germany)

## FAQ

### What does Pacira Pharmaceuticals invest in?

Pacira Pharmaceuticals invests primarily in Biotechnology, Medical and Health Care startups, most often at Convertible Note and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Pacira Pharmaceuticals?

Public channels for Pacira Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pacira Pharmaceuticals?

The team at Pacira Pharmaceuticals includes Charles A. Reinhart III (Chief Financial Officer), Dennis McLoughlin (Area Sales Director) and Paul R. Ellwood (Vice President, Human Resources), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co